INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
Source: SeekingAlpha
2026-02-27 00:07:50 ET
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB February 26, 2026 1:00 PM EST...
Read the full article on Seeking Alpha
For further details see:
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
INmune Bio Inc.
NASDAQ: INMB
INMB Trading
6.19% G/L:
$1.3327 Last:
31,105 Volume:
$1.30 Open:
INMB Latest News
February 23, 2026 09:25:00 am
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar
February 19, 2026 12:15:00 pm
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom(TM) for RDEB
INMB Stock Data
$100,001,939
20,608,626
3.69%
19
N/A
Biotechnology & Life Sciences
Healthcare
US
Boca Raton
